ArticleJournal of gynecologic oncology2025

Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80).

Jung-Yun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.